Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events
Sean Singer(Harvard University), Nicole R. LeBoeuf(Dana-Farber Brigham Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Anna K. Dewan(Vanderbilt University Medical Center), Steven P. Treon(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Sally Tan(Harvard University)
Cited by 44
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k